1. Firstly, Likang V-0 1 optimized its safety and immunogenicity in structure and mechanism. Unlike other recombinant protein vaccines, which only contain COVID-19 RBD dimer, Likang V-0 1 is designed with IFN ι-Pan-RBD-Fc molecule based on global innovative patent technology. On the basis of RBD dimer, immune active components such as biological adjuvant interferon, pan epitope and FC can be fused, which can quickly activate and produce lasting immune response, and sequential immunization can produce neutralizing antibodies with high titer. Moreover, the traditional aluminum adjuvant is adopted, which breaks through the dependence of imported strong adjuvant monopolized by patents.
2. At the same time, Likang V-0 1 has also obtained the clinical protection data against Omicron. A number of real-world research data show that Likang V-0 1 has the same protective effect on Omicron as the international first-class vaccine. In terms of safety, Likang V-0 1 is also obviously superior to mRNA vaccine and adenovirus vaccine.
3. Moreover, Likang V-0 1 has strong stability and convenient storage and transportation. It is understood that Likang V-0 1 can be transported in the cold chain at 2-8℃ and stored for a long time, and it can still be stored for 6 months at 25℃. Compared with the mRNA vaccine that needs cryopreservation, P3 workshop is not needed for its production, and conventional GMP workshop can meet the requirements, which has obvious advantages in production, storage, transportation and cost.
4. Not only that, the independent and controllable advantages of the company's vaccine industry chain are more significant. It is understood that at present, the company's stock solution production line and preparation production line have passed the on-site inspection of vaccine production license of Guangdong Drug Administration and obtained the vaccine production license certificate. Up to now, the company's stock solution production capacity has reached 3.5 billion doses, and the preparation production capacity has reached 65.438+0.5 billion doses, indicating that the company can achieve a sustained and stable supply of vaccines after approval.
5. To sum up, it can be seen that the company has the ability of vaccine research and industrialization of the whole industry chain, and can further enrich the product pipeline and promote vaccine product research and development with high efficiency in the future. In this regard, the company also said that the follow-up research and development plan of mutant strain will mainly focus on the research and development of the next generation COVID-19 vaccine, including the bivalent vaccine of β+δ and bivalent vaccine containing the mutant strain of BA.5. In addition to vaccine research and development in COVID-19, the company will also lay out innovative research and development of other vaccine varieties in the future, and will also pay attention to vaccine varieties representing other technical routes in the future.